Clinical Trial Update: This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1. [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update on the combination of Sigvotatug Vedotin and pembrolizumab in people with non-small cell lung cancer expressing high levels of P…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Sigvotatug Vedotin

Snippet

Sponsor: Pfizer | Conditions: Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung | Phase 3 | Status: RECRUITING